Hawaii Senate Bill SB1427

Hawaii 2025 Regular Session

• Introduced: 1/23/25
• Refer: 1/27/25

Caption

Relating To Manufactured Hemp Products.

Summary

SB1427 clarifies Hawaii’s statutory definition of “manufactured hemp product” in chapter 328G, HRS. The bill amends the definition to expressly include not only hemp products already described in statute—such as orally consumed dietary supplements and topical products—but also any additional hemp products that the Department of Health may specify by rule under section 328G-4. It also preserves the exclusion of living hemp plants, viable seeds, leaf materials, and floral materials from the definition. The measure is framed as a technical correction to address an ambiguity created by Act 263 (2023). According to the bill findings, the prior amendment may have unintentionally limited the Department of Health’s authority to regulate new hemp product types as they emerge. SB1427 is intended to restore and clarify that rulemaking authority so the department can continue to classify and regulate manufactured hemp products through administrative rules.

Impact

If enacted, SB1427 would amend section 328G-1, Hawaii Revised Statutes, to broaden and clarify the scope of “manufactured hemp product” for regulatory purposes. The Department of Health would retain explicit authority to designate additional hemp products by rule under section 328G-4, which could affect manufacturers, distributors, retailers, and consumers of hemp-derived goods. The bill does not create a new regulatory program, but it strengthens the legal basis for existing and future DOH hemp-product rules and reduces the risk that new product categories fall outside state oversight.

Sentiment

The available bill materials suggest generally neutral to supportive sentiment, with the measure presented as a housekeeping clarification rather than a policy shift. There are no recorded committee transcripts or votes in the provided context, so there is no evidence of formal opposition or debate. The bill’s framing as a correction to an inadvertent ambiguity indicates an intent to preserve existing regulatory authority rather than expand it in a controversial way.

Contention

The main point of potential contention is the scope of the Department of Health’s rulemaking authority. Supporters would likely view the bill as necessary to ensure the department can keep pace with evolving hemp products and maintain consumer and public health oversight. Any concern would likely come from hemp businesses or advocates worried that broader administrative discretion could lead to more restrictive regulation, uncertainty, or future classification of additional products as regulated manufactured hemp products. The bill text itself does not identify any specific opponents or disputed provisions.